A revolutionary clinical trial in the United States is exploring the possibility of extending the lifespan of dogs. Known as the STAY study, this research is spearheaded by Loyal, a San Francisco-based animal health company. If successful, this breakthrough could reshape veterinary medicine and offer pet owners more cherished years with their furry companions.
Inside the STAY Study: How It Works
The STAY study is a double-blind, placebo-controlled clinical trial, meaning neither the participating dogs nor the veterinarians administering the treatment know which dogs are receiving the actual drug. This method ensures unbiased results and maintains scientific rigor.
Over 1,000 senior dogs have been enrolled in the study, with each dog required to take the medication daily for up to four years. According to Dr. Alex Robb, Medical Director at Goodheart Animal Health Center in Colorado (one of the participating clinics), “At the end of the study, we will finally know if this drug truly works.”
Loyal aims to submit the trial’s findings to the U.S. Food and Drug Administration (FDA) for conditional approval, provided the results are promising.
The Goal: Slowing Down the Ageing Process
The primary objective of this drug is to slow the ageing process in dogs, enabling them to live longer, healthier lives. Despite significant advancements in veterinary care, a dog’s lifespan hasn’t improved as dramatically as that of humans. This is largely due to their faster metabolic rate, which leads to quicker cellular aging and physical decline.
While healthy dogs typically live between 10 to 15 years, depending on breed and size, the STAY study hopes to shift this reality by addressing the biological factors that contribute to ageing.
Eligibility Criteria for Dog Participants
Dogs must meet specific criteria to participate in the STAY study:
- Must be at least 10 years old
- Weigh 6.3 kg (14 pounds) or more
- Receive primary care from a participating study clinic
- Attend six clinic visits in the first year, followed by two visits per year for the next three years
- Owners must commit to the entire four-year study duration
Loyal is actively seeking more participants to strengthen the trial’s data pool, with hopes of applying for FDA approval by the end of the year.
Why Do Dogs Have Shorter Lifespans?
Dogs age faster than humans due to their accelerated metabolic rates, causing quicker cellular breakdown and reduced longevity. Although modern veterinary medicine has made notable progress, these advancements are relatively new compared to human healthcare, which explains the limited increase in canine lifespans over the decades.
A Potential Breakthrough for Pet Owners
If the STAY study proves successful, it could pave the way for innovative treatments that not only extend a dog’s lifespan but also enhance their quality of life during their senior years. For pet owners, this could mean more joyful moments, companionship, and precious memories with their beloved dogs.
This trial represents more than just scientific progress—it offers hope to millions of dog lovers worldwide who wish for nothing more than a few extra years with their best friends.